drugset / Trial / NCT03237832
A Phase 1 Study of ARN-6039
RandomizedParallel-groupQuadruple-blindHealth-services research
Summary
This Phase 1 study intends to determine the safety and tolerability of ARN-6039 in healthy subjects.
Timeline
- Start
- 2016-05-16
- Primary completion
- 2016-10-06
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ARN-6039 | Unknown | 50 mg | Oral |
| Comparator | ARN-6039 | Unknown | 100 mg | Oral |
| Comparator | ARN-6039 | Unknown | 150 mg | Oral |
| Comparator | ARN-6039 | Unknown | 200 mg | Oral |
| Comparator | ARN-6039 | Unknown | 300 mg | Oral |